[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fc3eh_69IfeI99r_ugNOoXOZXO7LJ6ultNDGoqkyFMKI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":83,"rows":90},"Fundacion Clinic per a la Recerca Biomédica",[4],60,false,23,6,16458,33,22,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"HIV",3,{"name":18,"count":16},"Nevi and Melanomas",{"name":20,"count":21},"Hepatocellular Carcinoma",2,{"name":23,"count":21},"Kidney Transplant Rejection",{"name":25,"count":21},"HIV-1-infection",{"name":27,"count":21},"Airway Management",{"name":29,"count":21},"Hepatitis C",{"name":31,"count":21},"Melanoma (Skin Cancer)",[33,38,43,48,53,58,63,68,73,78],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06097455","First in Human Study of the Infusion of ARI0003 Cells in Relapsed\u002FRefractory to Treatment B-cell Aggressive Lymphoma","2025-04-15","ARI0003",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05772286","Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults","2025-06","763SIP8\u002FMPLA-5 vaccine",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06830733","Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia","2025-12","ARI0002h",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06605417","Understanding the Transition from Normal Melanocytes to Nevus to Melanoma","2026-03-31","Methylomics",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06605443","Precision Medicine for L\u002FGCMN and Melanoma 2","2026-09-01","Liquid biopsy",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06896617","Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)","2026-11-20","Estradiol + Progesterone",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07169643","Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)","2026-12","Darbepoetin",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05398679","Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","2026-12-30","Cefaclor",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07270874","Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure","2027-08","Saline solution",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06852625","Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients","2028-03","Autologous Tolerogenic Dendritic Cells",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,147,165,183,201,219,237,255,273,291,309,327,345,363,381,399,417,435,459,483,501,527,549,571,598,623,654,680,701,724,756,774,792,810,835,859,888,906,924,942,960,987,1005,1030,1055,1080,1098,1128,1146,1174,1192,1210,1228,1252,1280,1298,1316,1334,1360,1385,1403,1428,1452,1477,1501,1529,1547,1573,1597,1622],{"intervention":92,"totalTrials":21,"cells":93},"Moxifloxacin",{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":145},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":144,"soonestReadout":71},[105,133],{"nctId":69,"briefTitle":70,"status":106,"phases":107,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"RECRUITING",[88],"2027-12-30","2022-08-17",360,[112],"Endocarditis Infective",[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],"Ciprofloxacin","Clindamycin Oral","Clindamycin","Dicloxacillin Oral","Dicloxacillin","Fusidic Acid Only Product in Oral Dose Form","Fusidic Acid Only Product in Parenteral Dose Form","Levofloxacin Oral","Levofloxacin","Linezolid Oral","Linezolid Injectable Product","Moxifloxacin Injectable Product","Rifampicin Only Product in Oral Dose Form","Rifampicin Only Product in Parenteral Dose Form","Sulfamethoxazole \u002F Trimethoprim Oral Tablet [Bactrim]","Sulfamethoxazole \u002F Trimethoprim Injectable Product","Tedizolid Oral","Tedizolid","Amoxicillin",{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT01091493","Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy","COMPLETED",[88],"2018-07-05","2010-07",73,[142],"Chronic Obstructive Pulmonary Disease",[92],1,{"trials":146,"activeCount":96},[],{"intervention":72,"totalTrials":144,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":163},{"trials":150,"activeCount":96},[],{"trials":152,"activeCount":96},[],{"trials":154,"activeCount":96},[],{"trials":156,"activeCount":96},[],{"trials":158,"activeCount":144,"soonestReadout":71},[159],{"nctId":69,"briefTitle":70,"status":106,"phases":160,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":161,"interventions":162},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":164,"activeCount":96},[],{"intervention":114,"totalTrials":144,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":181},{"trials":168,"activeCount":96},[],{"trials":170,"activeCount":96},[],{"trials":172,"activeCount":96},[],{"trials":174,"activeCount":96},[],{"trials":176,"activeCount":144,"soonestReadout":71},[177],{"nctId":69,"briefTitle":70,"status":106,"phases":178,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":179,"interventions":180},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":182,"activeCount":96},[],{"intervention":115,"totalTrials":144,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":199},{"trials":186,"activeCount":96},[],{"trials":188,"activeCount":96},[],{"trials":190,"activeCount":96},[],{"trials":192,"activeCount":96},[],{"trials":194,"activeCount":144,"soonestReadout":71},[195],{"nctId":69,"briefTitle":70,"status":106,"phases":196,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":197,"interventions":198},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":200,"activeCount":96},[],{"intervention":117,"totalTrials":144,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":217},{"trials":204,"activeCount":96},[],{"trials":206,"activeCount":96},[],{"trials":208,"activeCount":96},[],{"trials":210,"activeCount":96},[],{"trials":212,"activeCount":144,"soonestReadout":71},[213],{"nctId":69,"briefTitle":70,"status":106,"phases":214,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":215,"interventions":216},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":218,"activeCount":96},[],{"intervention":119,"totalTrials":144,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":235},{"trials":222,"activeCount":96},[],{"trials":224,"activeCount":96},[],{"trials":226,"activeCount":96},[],{"trials":228,"activeCount":96},[],{"trials":230,"activeCount":144,"soonestReadout":71},[231],{"nctId":69,"briefTitle":70,"status":106,"phases":232,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":233,"interventions":234},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":236,"activeCount":96},[],{"intervention":120,"totalTrials":144,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":253},{"trials":240,"activeCount":96},[],{"trials":242,"activeCount":96},[],{"trials":244,"activeCount":96},[],{"trials":246,"activeCount":96},[],{"trials":248,"activeCount":144,"soonestReadout":71},[249],{"nctId":69,"briefTitle":70,"status":106,"phases":250,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":251,"interventions":252},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":254,"activeCount":96},[],{"intervention":121,"totalTrials":144,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":96},[],{"trials":260,"activeCount":96},[],{"trials":262,"activeCount":96},[],{"trials":264,"activeCount":96},[],{"trials":266,"activeCount":144,"soonestReadout":71},[267],{"nctId":69,"briefTitle":70,"status":106,"phases":268,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":269,"interventions":270},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":272,"activeCount":96},[],{"intervention":123,"totalTrials":144,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":289},{"trials":276,"activeCount":96},[],{"trials":278,"activeCount":96},[],{"trials":280,"activeCount":96},[],{"trials":282,"activeCount":96},[],{"trials":284,"activeCount":144,"soonestReadout":71},[285],{"nctId":69,"briefTitle":70,"status":106,"phases":286,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":287,"interventions":288},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":290,"activeCount":96},[],{"intervention":124,"totalTrials":144,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":307},{"trials":294,"activeCount":96},[],{"trials":296,"activeCount":96},[],{"trials":298,"activeCount":96},[],{"trials":300,"activeCount":96},[],{"trials":302,"activeCount":144,"soonestReadout":71},[303],{"nctId":69,"briefTitle":70,"status":106,"phases":304,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":305,"interventions":306},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":308,"activeCount":96},[],{"intervention":125,"totalTrials":144,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":325},{"trials":312,"activeCount":96},[],{"trials":314,"activeCount":96},[],{"trials":316,"activeCount":96},[],{"trials":318,"activeCount":96},[],{"trials":320,"activeCount":144,"soonestReadout":71},[321],{"nctId":69,"briefTitle":70,"status":106,"phases":322,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":323,"interventions":324},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":326,"activeCount":96},[],{"intervention":126,"totalTrials":144,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":337,"NA":343},{"trials":330,"activeCount":96},[],{"trials":332,"activeCount":96},[],{"trials":334,"activeCount":96},[],{"trials":336,"activeCount":96},[],{"trials":338,"activeCount":144,"soonestReadout":71},[339],{"nctId":69,"briefTitle":70,"status":106,"phases":340,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":341,"interventions":342},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":344,"activeCount":96},[],{"intervention":127,"totalTrials":144,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":361},{"trials":348,"activeCount":96},[],{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":96},[],{"trials":354,"activeCount":96},[],{"trials":356,"activeCount":144,"soonestReadout":71},[357],{"nctId":69,"briefTitle":70,"status":106,"phases":358,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":359,"interventions":360},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":362,"activeCount":96},[],{"intervention":128,"totalTrials":144,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":379},{"trials":366,"activeCount":96},[],{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":96},[],{"trials":372,"activeCount":96},[],{"trials":374,"activeCount":144,"soonestReadout":71},[375],{"nctId":69,"briefTitle":70,"status":106,"phases":376,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":377,"interventions":378},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":380,"activeCount":96},[],{"intervention":129,"totalTrials":144,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":397},{"trials":384,"activeCount":96},[],{"trials":386,"activeCount":96},[],{"trials":388,"activeCount":96},[],{"trials":390,"activeCount":96},[],{"trials":392,"activeCount":144,"soonestReadout":71},[393],{"nctId":69,"briefTitle":70,"status":106,"phases":394,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":395,"interventions":396},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":398,"activeCount":96},[],{"intervention":130,"totalTrials":144,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":415},{"trials":402,"activeCount":96},[],{"trials":404,"activeCount":96},[],{"trials":406,"activeCount":96},[],{"trials":408,"activeCount":96},[],{"trials":410,"activeCount":144,"soonestReadout":71},[411],{"nctId":69,"briefTitle":70,"status":106,"phases":412,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":413,"interventions":414},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":416,"activeCount":96},[],{"intervention":132,"totalTrials":144,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":427,"NA":433},{"trials":420,"activeCount":96},[],{"trials":422,"activeCount":96},[],{"trials":424,"activeCount":96},[],{"trials":426,"activeCount":96},[],{"trials":428,"activeCount":144,"soonestReadout":71},[429],{"nctId":69,"briefTitle":70,"status":106,"phases":430,"primaryCompletion":71,"completion":108,"start":109,"enrollment":110,"conditions":431,"interventions":432},[88],[112],[72,114,114,115,116,117,118,119,120,121,122,123,124,92,125,126,127,128,129,130,131,132,132,72],{"trials":434,"activeCount":96},[],{"intervention":77,"totalTrials":144,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":457},{"trials":438,"activeCount":96},[],{"trials":440,"activeCount":96},[],{"trials":442,"activeCount":96},[],{"trials":444,"activeCount":96},[],{"trials":446,"activeCount":144,"soonestReadout":76},[447],{"nctId":74,"briefTitle":75,"status":448,"phases":449,"primaryCompletion":76,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":456},"NOT_YET_RECRUITING",[88],"2028-02","2026-01",114,[454,455],"Decompensated Cirrhosis","AKI - Acute Kidney Injury",[77],{"trials":458,"activeCount":96},[],{"intervention":62,"totalTrials":144,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":481},{"trials":462,"activeCount":96},[],{"trials":464,"activeCount":96},[],{"trials":466,"activeCount":96},[],{"trials":468,"activeCount":96},[],{"trials":470,"activeCount":144,"soonestReadout":61},[471],{"nctId":59,"briefTitle":60,"status":106,"phases":472,"primaryCompletion":61,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":479},[88],"2026-12-20","2025-02-01",334,[477,478],"Infertilities","Embryo Transfer",[62,480],"Ovitrelle",{"trials":482,"activeCount":96},[],{"intervention":480,"totalTrials":144,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":499},{"trials":486,"activeCount":96},[],{"trials":488,"activeCount":96},[],{"trials":490,"activeCount":96},[],{"trials":492,"activeCount":96},[],{"trials":494,"activeCount":144,"soonestReadout":61},[495],{"nctId":59,"briefTitle":60,"status":106,"phases":496,"primaryCompletion":61,"completion":473,"start":474,"enrollment":475,"conditions":497,"interventions":498},[88],[477,478],[62,480],{"trials":500,"activeCount":96},[],{"intervention":502,"totalTrials":144,"cells":503},"Sex hormones and modulators of the genital system.",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":525},{"trials":505,"activeCount":96},[],{"trials":507,"activeCount":96},[],{"trials":509,"activeCount":96},[],{"trials":511,"activeCount":96},[],{"trials":513,"activeCount":144,"soonestReadout":518},[514],{"nctId":515,"briefTitle":516,"status":448,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":524},"NCT07412873","Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer",[88],"2028-11-30","2029-06-30","2026-03-02",120,[523],"Cervical Cancer",[502],{"trials":526,"activeCount":96},[],{"intervention":67,"totalTrials":144,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":545,"NA":547},{"trials":530,"activeCount":96},[],{"trials":532,"activeCount":96},[],{"trials":534,"activeCount":96},[],{"trials":536,"activeCount":144,"soonestReadout":66},[537],{"nctId":64,"briefTitle":65,"status":106,"phases":538,"primaryCompletion":66,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},[87],"2027-06","2025-11-25",140,[543],"Liver Transplant; Complications",[67],{"trials":546,"activeCount":96},[],{"trials":548,"activeCount":96},[],{"intervention":47,"totalTrials":144,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":565,"PHASE4":567,"NA":569},{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[],{"trials":556,"activeCount":144,"soonestReadout":46},[557],{"nctId":44,"briefTitle":45,"status":448,"phases":558,"primaryCompletion":46,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":564},[86],"2027-12","2025-04",25,[563],"Leukemia, Plasma Cell",[47],{"trials":566,"activeCount":96},[],{"trials":568,"activeCount":96},[],{"trials":570,"activeCount":96},[],{"intervention":572,"totalTrials":144,"cells":573},"Radiotracer",{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":592,"PHASE4":594,"NA":596},{"trials":575,"activeCount":96},[],{"trials":577,"activeCount":96},[],{"trials":579,"activeCount":144,"soonestReadout":585},[580],{"nctId":581,"briefTitle":582,"status":583,"phases":584,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT07105384","Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy","ACTIVE_NOT_RECRUITING",[86],"2028-06-20","2028-12-20","2025-02-04",66,[590],"Parkinson Disease",[572],{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":96},[],{"trials":597,"activeCount":96},[],{"intervention":599,"totalTrials":144,"cells":600},"Atezolizumab and Bevacizumab",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":602,"activeCount":96},[],{"trials":604,"activeCount":96},[],{"trials":606,"activeCount":144,"soonestReadout":611},[607],{"nctId":608,"briefTitle":609,"status":448,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":616},"NCT07018947","Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC",[86],"2030-11","2025-11",90,[615],"Resectable Hepatocellular Carcinoma",[599],{"trials":618,"activeCount":96},[],{"trials":620,"activeCount":96},[],{"trials":622,"activeCount":96},[],{"intervention":624,"totalTrials":21,"cells":625},"Autologous Tolerogenic Dendritic cells",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":627,"activeCount":96},[],{"trials":629,"activeCount":21,"soonestReadout":81},[630,640],{"nctId":631,"briefTitle":632,"status":106,"phases":633,"primaryCompletion":634,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":639},"NCT07163403","First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers",[85],"2028-09-20","2025-09-04",20,[638],"Lynch Syndrome",[624],{"nctId":79,"briefTitle":80,"status":448,"phases":641,"primaryCompletion":81,"completion":81,"start":642,"enrollment":643,"conditions":644,"interventions":645},[85],"2025-05",30,[23],[82],{"trials":647,"activeCount":96},[],{"trials":649,"activeCount":96},[],{"trials":651,"activeCount":96},[],{"trials":653,"activeCount":96},[],{"intervention":655,"totalTrials":144,"cells":656},"CD5CAR-CBNK",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":672,"PHASE3":674,"PHASE4":676,"NA":678},{"trials":658,"activeCount":96},[],{"trials":660,"activeCount":144,"soonestReadout":665},[661],{"nctId":662,"briefTitle":663,"status":448,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT07454122","CD5CAR-NK Cells for Refractory Invasive Mold Disease",[85],"2029-05","2029-12","2026-05",10,[670],"Fungal Infection",[655],{"trials":673,"activeCount":96},[],{"trials":675,"activeCount":96},[],{"trials":677,"activeCount":96},[],{"trials":679,"activeCount":96},[],{"intervention":42,"totalTrials":144,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":693,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":683,"activeCount":96},[],{"trials":685,"activeCount":144,"soonestReadout":41},[686],{"nctId":39,"briefTitle":40,"status":583,"phases":687,"primaryCompletion":41,"completion":41,"start":688,"enrollment":689,"conditions":690,"interventions":692},[85],"2023-07-24",12,[691],"Healthy",[42],{"trials":694,"activeCount":96},[],{"trials":696,"activeCount":96},[],{"trials":698,"activeCount":96},[],{"trials":700,"activeCount":96},[],{"intervention":37,"totalTrials":144,"cells":702},{"EARLY_PHASE1":703,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":704,"activeCount":144,"soonestReadout":36},[705],{"nctId":34,"briefTitle":35,"status":448,"phases":706,"primaryCompletion":36,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":713},[84],"2027-01-15","2024-01-15",40,[711,712],"Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma",[37],{"trials":715,"activeCount":96},[],{"trials":717,"activeCount":96},[],{"trials":719,"activeCount":96},[],{"trials":721,"activeCount":96},[],{"trials":723,"activeCount":96},[],{"intervention":57,"totalTrials":21,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":727,"activeCount":96},[],{"trials":729,"activeCount":96},[],{"trials":731,"activeCount":96},[],{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":21,"soonestReadout":51},[738,749],{"nctId":49,"briefTitle":50,"status":106,"phases":739,"primaryCompletion":51,"completion":740,"start":741,"enrollment":742,"conditions":743,"interventions":746},[],"2026-11-30","2024-01-01",100,[744,745,18],"Congenital Melanocytic Nevi","Melanoma, Skin",[52,747,748,57],"RNA sequencing","Spatial transcriptomics",{"nctId":54,"briefTitle":55,"status":106,"phases":750,"primaryCompletion":56,"completion":751,"start":752,"enrollment":742,"conditions":753,"interventions":755},[],"2026-12-01","2025-01-01",[31,18,754],"Congenital Melanocytic Nevus",[57],{"intervention":52,"totalTrials":144,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":759,"activeCount":96},[],{"trials":761,"activeCount":96},[],{"trials":763,"activeCount":96},[],{"trials":765,"activeCount":96},[],{"trials":767,"activeCount":96},[],{"trials":769,"activeCount":144,"soonestReadout":51},[770],{"nctId":49,"briefTitle":50,"status":106,"phases":771,"primaryCompletion":51,"completion":740,"start":741,"enrollment":742,"conditions":772,"interventions":773},[],[744,745,18],[52,747,748,57],{"intervention":747,"totalTrials":144,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":786},{"trials":777,"activeCount":96},[],{"trials":779,"activeCount":96},[],{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":96},[],{"trials":785,"activeCount":96},[],{"trials":787,"activeCount":144,"soonestReadout":51},[788],{"nctId":49,"briefTitle":50,"status":106,"phases":789,"primaryCompletion":51,"completion":740,"start":741,"enrollment":742,"conditions":790,"interventions":791},[],[744,745,18],[52,747,748,57],{"intervention":748,"totalTrials":144,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":795,"activeCount":96},[],{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"trials":803,"activeCount":96},[],{"trials":805,"activeCount":144,"soonestReadout":51},[806],{"nctId":49,"briefTitle":50,"status":106,"phases":807,"primaryCompletion":51,"completion":740,"start":741,"enrollment":742,"conditions":808,"interventions":809},[],[744,745,18],[52,747,748,57],{"intervention":811,"totalTrials":144,"cells":812},"Sivextro 200 milligrams Oral",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":833},{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":96},[823],{"nctId":824,"briefTitle":825,"status":136,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":643,"conditions":830,"interventions":832},"NCT03746327","Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal",[88],"2024-01-31","2024-03-10","2020-02-13",[831],"Prostheses Infection",[811],{"trials":834,"activeCount":96},[],{"intervention":836,"totalTrials":144,"cells":837},"Doravirine 100Mg Tab",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":857},{"trials":839,"activeCount":96},[],{"trials":841,"activeCount":96},[],{"trials":843,"activeCount":96},[],{"trials":845,"activeCount":96},[],{"trials":847,"activeCount":96},[848],{"nctId":849,"briefTitle":850,"status":851,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":689,"conditions":855,"interventions":856},"NCT05506605","Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance","UNKNOWN",[88],"2024-12","2022-12-12",[25],[836],{"trials":858,"activeCount":96},[],{"intervention":860,"totalTrials":144,"cells":861},"Lamivudine 300 MG",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":886},{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":96},[],{"trials":867,"activeCount":96},[],{"trials":869,"activeCount":96},[],{"trials":871,"activeCount":96},[872],{"nctId":873,"briefTitle":874,"status":136,"phases":875,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":879,"interventions":881},"NCT03360682","Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients",[88],"2020-05-21","2018-04-13",19,[25,880],"Solid Organ Transplant",[860,882,883,884,885],"Abacavir 600 MG","Dolutegravir 50 mg","Tenofovir Disoproxil 245Mg","Emtricitabine 200 MG",{"trials":887,"activeCount":96},[],{"intervention":882,"totalTrials":144,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":904},{"trials":891,"activeCount":96},[],{"trials":893,"activeCount":96},[],{"trials":895,"activeCount":96},[],{"trials":897,"activeCount":96},[],{"trials":899,"activeCount":96},[900],{"nctId":873,"briefTitle":874,"status":136,"phases":901,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":902,"interventions":903},[88],[25,880],[860,882,883,884,885],{"trials":905,"activeCount":96},[],{"intervention":883,"totalTrials":144,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":922},{"trials":909,"activeCount":96},[],{"trials":911,"activeCount":96},[],{"trials":913,"activeCount":96},[],{"trials":915,"activeCount":96},[],{"trials":917,"activeCount":96},[918],{"nctId":873,"briefTitle":874,"status":136,"phases":919,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":920,"interventions":921},[88],[25,880],[860,882,883,884,885],{"trials":923,"activeCount":96},[],{"intervention":884,"totalTrials":144,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":940},{"trials":927,"activeCount":96},[],{"trials":929,"activeCount":96},[],{"trials":931,"activeCount":96},[],{"trials":933,"activeCount":96},[],{"trials":935,"activeCount":96},[936],{"nctId":873,"briefTitle":874,"status":136,"phases":937,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":938,"interventions":939},[88],[25,880],[860,882,883,884,885],{"trials":941,"activeCount":96},[],{"intervention":885,"totalTrials":144,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":952,"NA":958},{"trials":945,"activeCount":96},[],{"trials":947,"activeCount":96},[],{"trials":949,"activeCount":96},[],{"trials":951,"activeCount":96},[],{"trials":953,"activeCount":96},[954],{"nctId":873,"briefTitle":874,"status":136,"phases":955,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":956,"interventions":957},[88],[25,880],[860,882,883,884,885],{"trials":959,"activeCount":96},[],{"intervention":961,"totalTrials":144,"cells":962},"Abatacept",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":971,"NA":985},{"trials":964,"activeCount":96},[],{"trials":966,"activeCount":96},[],{"trials":968,"activeCount":96},[],{"trials":970,"activeCount":96},[],{"trials":972,"activeCount":96},[973],{"nctId":974,"briefTitle":975,"status":136,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT03669367","EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)",[88],"2022-06-30","2024-09-30","2019-06-03",70,[982],"Palindromic Rheumatism, Wrist",[961,984],"hydroxycloroquina",{"trials":986,"activeCount":96},[],{"intervention":984,"totalTrials":144,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":1003},{"trials":990,"activeCount":96},[],{"trials":992,"activeCount":96},[],{"trials":994,"activeCount":96},[],{"trials":996,"activeCount":96},[],{"trials":998,"activeCount":96},[999],{"nctId":974,"briefTitle":975,"status":136,"phases":1000,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":1001,"interventions":1002},[88],[982],[961,984],{"trials":1004,"activeCount":96},[],{"intervention":1006,"totalTrials":144,"cells":1007},"Biktarvy 50 mg\u002F200 mg\u002F25 mg film-coated",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1016,"NA":1028},{"trials":1009,"activeCount":96},[],{"trials":1011,"activeCount":96},[],{"trials":1013,"activeCount":96},[],{"trials":1015,"activeCount":96},[],{"trials":1017,"activeCount":96},[1018],{"nctId":1019,"briefTitle":1020,"status":136,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":709,"conditions":1025,"interventions":1027},"NCT05602506","Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide in Virologically Suppressed HIV-infected Adults",[88],"2024-03-15","2024-06-05","2022-11-15",[1026],"HIV Infections",[1006],{"trials":1029,"activeCount":96},[],{"intervention":1031,"totalTrials":144,"cells":1032},"gemcitabine, cisplatin and bevacizumab",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1053},{"trials":1034,"activeCount":96},[],{"trials":1036,"activeCount":96},[],{"trials":1038,"activeCount":96},[],{"trials":1040,"activeCount":96},[],{"trials":1042,"activeCount":96},[1043],{"nctId":1044,"briefTitle":1045,"status":136,"phases":1046,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":878,"conditions":1050,"interventions":1052},"NCT02316327","Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab",[88],"2016-09","2016-10","2013-07",[1051],"Non-Small Cell Lung Cancer (NSCLC)",[1031],{"trials":1054,"activeCount":96},[],{"intervention":1056,"totalTrials":144,"cells":1057},"Tenofovir + emtricitabine",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1066,"NA":1078},{"trials":1059,"activeCount":96},[],{"trials":1061,"activeCount":96},[],{"trials":1063,"activeCount":96},[],{"trials":1065,"activeCount":96},[],{"trials":1067,"activeCount":96},[1068],{"nctId":1069,"briefTitle":1070,"status":136,"phases":1071,"primaryCompletion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1076},"NCT02198443","Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir\u002FEmtricitabine (Truvada ®) + Lopinavir\u002FRitonavir (Kaletra ®) vs Tenofovir\u002FEmtricitabine\u002FCobicistat\u002FElvitegravir (Stribild ®). Prospective, Randomized, Open.",[88],"2016-07-15","2015-06-06",160,[15],[1056,1077],"elvitegravir\u002Fcobicistat\u002Femtricitabine\u002FTenofovir-Disoproxil",{"trials":1079,"activeCount":96},[],{"intervention":1077,"totalTrials":144,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1096},{"trials":1083,"activeCount":96},[],{"trials":1085,"activeCount":96},[],{"trials":1087,"activeCount":96},[],{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":96},[1092],{"nctId":1069,"briefTitle":1070,"status":136,"phases":1093,"primaryCompletion":1072,"start":1073,"enrollment":1074,"conditions":1094,"interventions":1095},[88],[15],[1056,1077],{"trials":1097,"activeCount":96},[],{"intervention":1099,"totalTrials":144,"cells":1100},"Steroid Drug",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1124,"NA":1126},{"trials":1102,"activeCount":96},[],{"trials":1104,"activeCount":96},[],{"trials":1106,"activeCount":96},[],{"trials":1108,"activeCount":96},[1109],{"nctId":1110,"briefTitle":1111,"status":136,"phases":1112,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1122},"NCT04831086","To Optimize Antenatal Management of Women With Pre Term Labor Using Amniocentesis",[87],"2024-10-30","2024-12-30","2021-05-05",247,[1118,1119,1120,1121],"Preterm Birth","Preterm Labor","Intra-amniotic Infection","Amniocentesis Affecting Fetus or Newborn",[1099,1123],"Tocolytic Agents",{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"intervention":1123,"totalTrials":144,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":96},[],{"trials":1135,"activeCount":96},[],{"trials":1137,"activeCount":96},[1138],{"nctId":1110,"briefTitle":1111,"status":136,"phases":1139,"primaryCompletion":1113,"completion":1114,"start":1115,"enrollment":1116,"conditions":1140,"interventions":1141},[87],[1118,1119,1120,1121],[1099,1123],{"trials":1143,"activeCount":96},[],{"trials":1145,"activeCount":96},[],{"intervention":1147,"totalTrials":144,"cells":1148},"Grazoprevir 100 mg\u002Fd 8 weeks",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1170,"NA":1172},{"trials":1150,"activeCount":96},[],{"trials":1152,"activeCount":96},[],{"trials":1154,"activeCount":96},[],{"trials":1156,"activeCount":96},[1157],{"nctId":1158,"briefTitle":1159,"status":851,"phases":1160,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1166},"NCT02897596","Efficacy of GZR\u002FEBR in Early Chronic Hepatitis C in HIV\u002FHCV Co-infected Patients",[87],"2019-04-28","2019-10-30","2017-04-28",62,[29,15],[1147,1167,1168,1169],"Elbasvir 50 mg\u002Fd 8 weeks","Grazoprevir 100 mg\u002Fd 12 weeks","Elbasvir 50 mg\u002Fd 12 weeks",{"trials":1171,"activeCount":96},[],{"trials":1173,"activeCount":96},[],{"intervention":1167,"totalTrials":144,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":96},[],{"trials":1179,"activeCount":96},[],{"trials":1181,"activeCount":96},[],{"trials":1183,"activeCount":96},[1184],{"nctId":1158,"briefTitle":1159,"status":851,"phases":1185,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1186,"interventions":1187},[87],[29,15],[1147,1167,1168,1169],{"trials":1189,"activeCount":96},[],{"trials":1191,"activeCount":96},[],{"intervention":1168,"totalTrials":144,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1206,"NA":1208},{"trials":1195,"activeCount":96},[],{"trials":1197,"activeCount":96},[],{"trials":1199,"activeCount":96},[],{"trials":1201,"activeCount":96},[1202],{"nctId":1158,"briefTitle":1159,"status":851,"phases":1203,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1204,"interventions":1205},[87],[29,15],[1147,1167,1168,1169],{"trials":1207,"activeCount":96},[],{"trials":1209,"activeCount":96},[],{"intervention":1169,"totalTrials":144,"cells":1211},{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1224,"NA":1226},{"trials":1213,"activeCount":96},[],{"trials":1215,"activeCount":96},[],{"trials":1217,"activeCount":96},[],{"trials":1219,"activeCount":96},[1220],{"nctId":1158,"briefTitle":1159,"status":851,"phases":1221,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1222,"interventions":1223},[87],[29,15],[1147,1167,1168,1169],{"trials":1225,"activeCount":96},[],{"trials":1227,"activeCount":96},[],{"intervention":1229,"totalTrials":144,"cells":1230},"Secretin",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1248,"NA":1250},{"trials":1232,"activeCount":96},[],{"trials":1234,"activeCount":96},[],{"trials":1236,"activeCount":96},[],{"trials":1238,"activeCount":96},[1239],{"nctId":1240,"briefTitle":1241,"status":851,"phases":1242,"primaryCompletion":1243,"completion":1243,"start":1244,"enrollment":541,"conditions":1245,"interventions":1247},"NCT05914077","Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.",[87],"2025-01","2023-09-13",[1246],"Intraductal Papillary Mucinous Neoplasm of Pancreas",[1229],{"trials":1249,"activeCount":96},[],{"trials":1251,"activeCount":96},[],{"intervention":1253,"totalTrials":144,"cells":1254},"Grazoprevir 100 mg\u002Fday",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1276,"NA":1278},{"trials":1256,"activeCount":96},[],{"trials":1258,"activeCount":96},[],{"trials":1260,"activeCount":96},[],{"trials":1262,"activeCount":96},[1263],{"nctId":1264,"briefTitle":1265,"status":1266,"phases":1267,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":96,"conditions":1270,"interventions":1272},"NCT02890719","Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.","WITHDRAWN",[87],"2017-06-01","2016-08-03",[1271,29],"Liver Transplantation",[1253,1273,1253,1274,1275],"Elbasvir 50 mg\u002Fd","Elbasvir 50 mg\u002Fday","Ribavirin 1200 mg\u002Fday",{"trials":1277,"activeCount":96},[],{"trials":1279,"activeCount":96},[],{"intervention":1273,"totalTrials":144,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1294,"NA":1296},{"trials":1283,"activeCount":96},[],{"trials":1285,"activeCount":96},[],{"trials":1287,"activeCount":96},[],{"trials":1289,"activeCount":96},[1290],{"nctId":1264,"briefTitle":1265,"status":1266,"phases":1291,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":96,"conditions":1292,"interventions":1293},[87],[1271,29],[1253,1273,1253,1274,1275],{"trials":1295,"activeCount":96},[],{"trials":1297,"activeCount":96},[],{"intervention":1274,"totalTrials":144,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":96},[],{"trials":1303,"activeCount":96},[],{"trials":1305,"activeCount":96},[],{"trials":1307,"activeCount":96},[1308],{"nctId":1264,"briefTitle":1265,"status":1266,"phases":1309,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":96,"conditions":1310,"interventions":1311},[87],[1271,29],[1253,1273,1253,1274,1275],{"trials":1313,"activeCount":96},[],{"trials":1315,"activeCount":96},[],{"intervention":1275,"totalTrials":144,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1330,"NA":1332},{"trials":1319,"activeCount":96},[],{"trials":1321,"activeCount":96},[],{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":96},[1326],{"nctId":1264,"briefTitle":1265,"status":1266,"phases":1327,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":96,"conditions":1328,"interventions":1329},[87],[1271,29],[1253,1273,1253,1274,1275],{"trials":1331,"activeCount":96},[],{"trials":1333,"activeCount":96},[],{"intervention":1335,"totalTrials":144,"cells":1336},"sapropterin",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1356,"NA":1358},{"trials":1338,"activeCount":96},[],{"trials":1340,"activeCount":96},[],{"trials":1342,"activeCount":96},[],{"trials":1344,"activeCount":96},[1345],{"nctId":1346,"briefTitle":1347,"status":136,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1355},"NCT01456286","Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension",[86,87],"2013-10","2011-10",42,[1353,1354],"Liver Cirrhosis","Portal Hypertension",[1335],{"trials":1357,"activeCount":96},[],{"trials":1359,"activeCount":96},[],{"intervention":1361,"totalTrials":144,"cells":1362},"Regorafenib",{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1364,"activeCount":96},[],{"trials":1366,"activeCount":96},[],{"trials":1368,"activeCount":96},[1369],{"nctId":1370,"briefTitle":1371,"status":136,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1377},"NCT04170556","Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)",[85,86],"2024-07-09","2020-03-16",69,[20],[1361,1378],"Nivolumab",{"trials":1380,"activeCount":96},[],{"trials":1382,"activeCount":96},[],{"trials":1384,"activeCount":96},[],{"intervention":1378,"totalTrials":144,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":96},[],{"trials":1390,"activeCount":96},[],{"trials":1392,"activeCount":96},[1393],{"nctId":1370,"briefTitle":1371,"status":136,"phases":1394,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":1375,"conditions":1395,"interventions":1396},[85,86],[20],[1361,1378],{"trials":1398,"activeCount":96},[],{"trials":1400,"activeCount":96},[],{"trials":1402,"activeCount":96},[],{"intervention":1404,"totalTrials":144,"cells":1405},"18F-Florbetaben",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1422,"PHASE4":1424,"NA":1426},{"trials":1407,"activeCount":96},[],{"trials":1409,"activeCount":96},[],{"trials":1411,"activeCount":96},[1412],{"nctId":1413,"briefTitle":1414,"status":1266,"phases":1415,"primaryCompletion":1416,"completion":1417,"start":1418,"enrollment":96,"conditions":1419,"interventions":1421},"NCT03057938","Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study",[86],"2022-01","2022-06","2020-07",[1420],"Subjective Cognitive Decline",[1404],{"trials":1423,"activeCount":96},[],{"trials":1425,"activeCount":96},[],{"trials":1427,"activeCount":96},[],{"intervention":1429,"totalTrials":144,"cells":1430},"Imlifidase",{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1432,"activeCount":96},[],{"trials":1434,"activeCount":96},[],{"trials":1436,"activeCount":96},[1437],{"nctId":1438,"briefTitle":1439,"status":1266,"phases":1440,"primaryCompletion":66,"completion":1441,"start":1442,"enrollment":96,"conditions":1443,"interventions":1445},"NCT06461546","Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients",[86],"2027-05","2024-10-22",[1444],"Kidney Transplant Candidates",[1429],{"trials":1447,"activeCount":96},[],{"trials":1449,"activeCount":96},[],{"trials":1451,"activeCount":96},[],{"intervention":1453,"totalTrials":144,"cells":1454},"Dendritic Cell Vaccine",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1456,"activeCount":96},[],{"trials":1458,"activeCount":96},[],{"trials":1460,"activeCount":96},[1461],{"nctId":1462,"briefTitle":1463,"status":136,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":1467,"conditions":1468,"interventions":1470},"NCT01413295","Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer",[86],"2014-09","2011-08",52,[1469],"Colorectal Neoplasms",[1453],{"trials":1472,"activeCount":96},[],{"trials":1474,"activeCount":96},[],{"trials":1476,"activeCount":96},[],{"intervention":1478,"totalTrials":144,"cells":1479},"Cabozantinib",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1481,"activeCount":96},[],{"trials":1483,"activeCount":96},[],{"trials":1485,"activeCount":96},[1486],{"nctId":1487,"briefTitle":1488,"status":136,"phases":1489,"primaryCompletion":1490,"completion":1490,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1494},"NCT04316182","Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)",[86],"2023-02-22","2020-07-31",24,[20],[1478],{"trials":1496,"activeCount":96},[],{"trials":1498,"activeCount":96},[],{"trials":1500,"activeCount":96},[],{"intervention":1502,"totalTrials":144,"cells":1503},"Plasma exchange",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1505,"activeCount":96},[],{"trials":1507,"activeCount":96},[],{"trials":1509,"activeCount":96},[1510],{"nctId":1511,"briefTitle":1512,"status":1513,"phases":1514,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":1519,"interventions":1521},"NCT04374539","Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","TERMINATED",[86],"2021-06-06","2021-06-29","2020-04-29",36,[1520],"Coronavirus",[1502,1522],"Standar medical treatmen",{"trials":1524,"activeCount":96},[],{"trials":1526,"activeCount":96},[],{"trials":1528,"activeCount":96},[],{"intervention":1522,"totalTrials":144,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[],{"trials":1536,"activeCount":96},[1537],{"nctId":1511,"briefTitle":1512,"status":1513,"phases":1538,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":1539,"interventions":1540},[86],[1520],[1502,1522],{"trials":1542,"activeCount":96},[],{"trials":1544,"activeCount":96},[],{"trials":1546,"activeCount":96},[],{"intervention":1548,"totalTrials":144,"cells":1549},"Albumin treatment",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1551,"activeCount":96},[],{"trials":1553,"activeCount":96},[],{"trials":1555,"activeCount":96},[1556],{"nctId":1557,"briefTitle":1558,"status":136,"phases":1559,"primaryCompletion":1560,"completion":1561,"start":1562,"enrollment":1467,"conditions":1563,"interventions":1566},"NCT03941405","Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)",[86],"2024-12-28","2025-01-30","2020-02-01",[1564,1565],"Hyponatremia With Excess Extracellular Fluid Volume","Cirrhosis, Liver",[1548],{"trials":1568,"activeCount":96},[],{"trials":1570,"activeCount":96},[],{"trials":1572,"activeCount":96},[],{"intervention":1574,"totalTrials":144,"cells":1575},"Tolerogenic Dendritic Cells",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1589,"PHASE3":1591,"PHASE4":1593,"NA":1595},{"trials":1577,"activeCount":96},[],{"trials":1579,"activeCount":96},[1580],{"nctId":1581,"briefTitle":1582,"status":1513,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":16,"conditions":1586,"interventions":1588},"NCT02622763","Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment",[85],"2019-05-05","2015-11",[1587],"Crohn's Disease",[1574],{"trials":1590,"activeCount":96},[],{"trials":1592,"activeCount":96},[],{"trials":1594,"activeCount":96},[],{"trials":1596,"activeCount":96},[],{"intervention":1598,"totalTrials":144,"cells":1599},"gadobutrol",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1601,"activeCount":96},[],{"trials":1603,"activeCount":96},[1604],{"nctId":1605,"briefTitle":1606,"status":136,"phases":1607,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1613},"NCT02274246","Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)",[85],"2015-03","2014-11",9,[1612],"Left Atrial Fibrosis",[1598],{"trials":1615,"activeCount":96},[],{"trials":1617,"activeCount":96},[],{"trials":1619,"activeCount":96},[],{"trials":1621,"activeCount":96},[],{"intervention":1623,"totalTrials":144,"cells":1624},"[F18]-FDDNP",{"EARLY_PHASE1":1625,"PHASE1":1639,"PHASE2":1641,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1626,"activeCount":96},[1627],{"nctId":1628,"briefTitle":1629,"status":136,"phases":1630,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":709,"conditions":1634,"interventions":1638},"NCT02214862","2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism",[84],"2015-12","2016-02","2013-03",[1635,1636,1637],"Progressive Supranuclear Palsy","Multi-System Atrophy","Parkinsonism",[1623],{"trials":1640,"activeCount":96},[],{"trials":1642,"activeCount":96},[],{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[],{"trials":1648,"activeCount":96},[]]